Hardman & Co Equity Research & Stock Reports
- Professional research and all the latest forecasts, valuation opinions and multiples from Hardman & Co's expert analysts.
- Real-time updates from analysts following company announcements and other events.
- Near-live share prices, user-friendly dashboard, charting and company content.
Making clinical progress
Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen’s proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. The results presentation is a good opportunity for Evgen to present the progress of its clinical pipeline. SFX-01 is progressing in two Phase II clinical trials for both subarachnoid haemorrhage (SAH) and ER+ metastatic breast cancer.
21 Jun 17
Positive judgement from the secondary market
Burford has announced a further sale from the Petersen case, the third in the last six months. On this occasion, they have sold 15% of the exposure for $66m, giving an implied value on the whole case of $440m. This is a 10% uplift on the value given by the previous sales, which was $400m. Having reduced their retained exposure to 75%, Burford have made commitments to keep at least 65% until the end of 2018 and at least 50.1% beyond that.
14 Jun 17
All Change From 2019
As weather patterns revert to more normal conditions, REA is hoping to see production levels rise across its oil palm plantations in Kalimantan during 2017. However, full recovery in oil palm production can take up to 18 months, so improvement in production will spread into 2018. Nevertheless, revenues should see growth of more than 20% y-o-y, helped too by contributions from the electricity generating operations and possibly, also by the coal mining activities, as demand for coal grows domestically and abroad, providing support for prices.
13 Jun 17
AVO AGY APH ARBB BUR CMH CLIG COS DNL EVG MCL MUR NSF ODX OXB PPH NIPT PHP SPH TRX TON
Despite the calling of a General Election for June 8th, the FTSE-100 continues to perform strongly, partly on the back of Wall Street and encouraging corporate figures. Since the surprise Election was called on April 18th, the FTSE-100 has advanced by over 5%. There has been no sign of political nerves as is normally the case with opinion polls conveying mixed messages.
02 Jun 17
Developing novel cancer therapies
ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are in clinical trials: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potential to treat other hormoneinduced indications; and VAL401 (Phase II) – a novel reformulation of risperidone, in trials for lung cancer. Both drugs are targeted at multi-billion dollar markets that are inadequately served by current drugs. The aim is to progress the clinical data and exit via a collaboration or commercial out-licensing to a larger partner.
31 May 17
A transformational year driving growth
Alliance Pharma’s buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma was transformational, doubling the size of the company and providing a more internationally-oriented business. The enlarged group is also a more attractive and credible partner for in–licensing and M&A opportunities. 2017 looks set to be an exciting year for the group: not only is there solid underlying growth potential in the re-focused group, but also regulatory approval of Diclectin offersfurthersignificant growth potential.
25 May 17
Hardman & Co Research and Daily Commentaries
Research Tree offers Hardman & Co research, providing ongoing coverage of 70 shares , as well as macro-economic categories including: Economic Data and Housing Market. We offer 194 reports from Hardman & Co on Research Tree.
Research reports provided by Hardman & Co
Companies covered by Hardman & Co
Sectors covered by Hardman & Co